Group One Trading
VNDA icon

Group One Trading’s Vanda Pharmaceuticals VNDA Stock Holding History

Group One Trading’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85K Buy
12,300
+8,500
+224% +$65.5K ﹤0.01% 4871
2025
Q4 		$33.5K Buy
+3,800
New +$20.9K ﹤0.01% 5927
2025
Q3 		– Sell
-41,200
Closed -$194K – 9224
2025
Q2 		$194K Buy
41,200
+9,600
+30% +$42K ﹤0.01% 4372
2025
Q1 		$145K Buy
31,600
+27,900
+754% +$130K ﹤0.01% 4282
2024
Q4 		$17.7K Sell
3,700
-15,200
-80% -$73K ﹤0.01% 5769
2024
Q3 		$88.6K Sell
18,900
-87,600
-82% -$470K ﹤0.01% 4276
2024
Q2 		$602K Buy
106,500
+69,000
+184% +$356K ﹤0.01% 2394
2024
Q1 		$154K Buy
+37,500
New +$150K ﹤0.01% 3777
2023
Q4 		– Sell
-5,000
Closed -$21.6K – 8254
2023
Q3 		$21.6K Buy
5,000
+4,800
+2,400% +$26.7K ﹤0.01% 5832
2023
Q2 		$1.32K Buy
+200
New +$1.28K ﹤0.01% 7203
2022
Q2 		– Sell
-100
Closed -$1K – 8587
2022
Q1 		$1K Sell
100
-14,400
-99% -$189K ﹤0.01% 7886
2021
Q4 		$228K Buy
14,500
+9,800
+209% +$171K ﹤0.01% 4955
2021
Q3 		$81K Buy
4,700
+3,500
+292% +$61.3K ﹤0.01% 6118
2021
Q2 		$26K Buy
+1,200
New +$21.5K ﹤0.01% 7039
2021
Q1 		– Sell
-700
Closed -$9K – 8065
2020
Q4 		$9K Hold
700
– – ﹤0.01% 5839
2020
Q3 		$7K Hold
700
– – ﹤0.01% 5548
2020
Q2 		$8K Buy
+700
New +$7.93K ﹤0.01% 5232
2020
Q1 		– Sell
-100
Closed -$2K – 5782
2019
Q4 		$2K Sell
100
-1,900
-95% -$28.7K ﹤0.01% 4924
2019
Q3 		$27K Buy
2,000
+900
+82% +$12.5K ﹤0.01% 4250
2019
Q2 		$16K Sell
1,100
-6,500
-86% -$103K ﹤0.01% 4266
2019
Q1 		$140K Buy
7,600
+6,700
+744% +$153K ﹤0.01% 2946
2018
Q4 		$24K Sell
900
-4,300
-83% -$101K ﹤0.01% 3956
2018
Q3 		$119K Sell
5,200
-5,400
-51% -$110K ﹤0.01% 3407
2018
Q2 		$202K Buy
10,600
+8,700
+458% +$145K ﹤0.01% 3047
2018
Q1 		$32K Sell
1,900
-100
-5% -$1.67K ﹤0.01% 3879
2017
Q4 		$30K Sell
2,000
-8,400
-81% -$125K ﹤0.01% 3989
2017
Q3 		$186K Buy
+10,400
New +$174K ﹤0.01% 2809
2017
Q2 		– Sell
-1,000
Closed -$14K – 5137
2017
Q1 		$14K Sell
1,000
-58,500
-98% -$834K ﹤0.01% 4020
2016
Q4 		$949K Sell
59,500
-9,300
-14% -$149K 0.01% 1342
2016
Q3 		$1.15M Buy
68,800
+63,100
+1,107% +$849K 0.01% 1185
2016
Q2 		$64K Sell
5,700
-8,500
-60% -$82.3K ﹤0.01% 3151
2016
Q1 		$119K Buy
14,200
+4,500
+46% +$36.9K ﹤0.01% 2713
2015
Q4 		$90K Sell
9,700
-7,800
-45% -$77.8K ﹤0.01% 3044
2015
Q3 		$197K Sell
17,500
-23,900
-58% -$292K ﹤0.01% 2508
2015
Q2 		$525K Buy
41,400
+17,300
+72% +$187K 0.01% 1742
2015
Q1 		$224K Sell
24,100
-180,700
-88% -$2.04M ﹤0.01% 2283
2014
Q4 		$2.93M Buy
204,800
+162,200
+381% +$1.92M 0.04% 463
2014
Q3 		$442K Sell
42,600
-35,200
-45% -$461K 0.01% 1716
2014
Q2 		$1.26M Sell
77,800
-201,300
-72% -$2.68M 0.02% 980
2014
Q1 		$4.54M Buy
279,100
+1,000
+0.4% +$14.2K 0.08% 262
2013
Q4 		$3.45M Buy
278,100
+146,700
+112% +$1.47M 0.05% 380
2013
Q3 		$1.44M Buy
131,400
+41,000
+45% +$438K 0.03% 751
2013
Q2 		$730K Buy
+90,400
New +$609K 0.02% 1050

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's VNDA Position: Q1 2026 in Review

Group One Trading sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 54,341 shares — an estimated $419K sold.

Group One Trading first reported a position in VNDA in Q2 2013 and held it in 36 quarters. The position peaked at $2.75M in Q4 2013. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Group One Trading reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 54,341 Vanda Pharmaceuticals shares in Q1 2026, an estimated $419K.
  • Group One Trading first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 36 quarters.
  • Group One Trading's Vanda Pharmaceuticals position peaked at $2.75M in Q4 2013.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.